Trial *
Publication Borges M, Revista Universidad, (2021) (published paper)
Dates: 2020-03-01 to 2020-04-30
Funding: Not reported/unclear
Conflict of interest: *

Methods
RCT
Location : * / Ecuador
Follow-up duration (days): 42
Inclusion criteria
  • Adults and children with signs and symptoms of SARS-CoV-2 and o2 saturation >90% at room air
  • controlled comorbidities
  • less than 15 days since symptoms appearance.
Exclusion criteria NR
Interventions
Treatment
Methisoprinol
Children: 50 mg/kg orally divided in four daily doses for 4 days; 50 mg/kg orally divided in three daily doses for 10 days Adults: Initial single dose of 1 g orally; 500 mg four times daily for 4 days; 500 mg three times daily for 14 days

Control
Standard care
*

Participants
Randomized
participants :
Methisoprinol=30
Standard care=30
Characteristics of participants
N= 60
Mean age : NR
0 males
Severity : Mild: n= 60/ Asymptomatic: n=0
Number of vaccinated participants: NR
Primary outcome
In the register
NR
In the report
NR
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Not reported
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
*
General comment This study was developed to determine a pilot protocol that generates fewer adverse effects, avoiding medical complications in symptomatic patients and reverse the clinical and imaging picture in patients treated with metisoprinol compared to controls. No study registry or protocol available. Published article with limited data to extract baseline characteristics/co-interventions per study arm, and to assess the overall risk of bias.Outcomes reported were no relevant for the COVID-19 NMA. Consequently, no outcome data have been extracted for this study.